Literature DB >> 26542147

Hand-foot syndrome following decitabine.

Alaa M Ali1, Meagan Jacoby2, John S Welch3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26542147      PMCID： PMC5175272          DOI： 10.1007/s00277-015-2546-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

1.  Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases.

Authors:  Z Demirçay; O Gürbüz; T B Alpdoğan; D Yücelten; O Alpdoğan; O Kurtkaya; M Bayik
Journal:  Int J Dermatol       Date:  1997-08       Impact factor: 2.736

2.  Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Authors:  Jean-Pierre Issa; Guillermo Garcia-Manero; Xuelin Huang; Jorge Cortes; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Mark Brandt; Sherry Pierce; Hagop M Kantarjian
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

Review 3.  The hand-foot-syndrome associated with medical tumor therapy - classification and management.

Authors:  Annette Degen; Mareike Alter; Florian Schenck; Imke Satzger; Bernward Völker; Alexander Kapp; Ralf Gutzmer
Journal:  J Dtsch Dermatol Ges       Date:  2010-05-06       Impact factor: 5.584

4.  Erythematous eruption of the palms and soles associated with mitotane therapy.

Authors:  R L Zuehlke
Journal:  Dermatologica       Date:  1974

5.  Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.

Authors:  Robert J Kim; Gertrude Peterson; Barbara Kulp; Kristine M Zanotti; Maurie Markman
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

6.  HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

Authors:  Vincent Sibaud; Florence Dalenc; Christine Chevreau; Henri Roché; Jean-Pierre Delord; Loïc Mourey; Jean-Louis Lacaze; Nora Rahhali; Charles Taïeb
Journal:  Oncologist       Date:  2011-09-30

7.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

8.  Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.

Authors:  M Lotem; A Hubert; O Lyass; M A Goldenhersh; A Ingber; T Peretz; A Gabizon
Journal:  Arch Dermatol       Date:  2000-12

Review 9.  Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

Authors:  Adam D Lipworth; Caroline Robert; Andrew X Zhu
Journal:  Oncology       Date:  2009-11-16       Impact factor: 2.935
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.